EBR Systems, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2026. The company generated net sales of $2.6 million for the three months ended June 30, 2026, a substantial increase from $170,000 in the same period last year. For the first half of 2026, net sales reached $5.0 million, compared to $170,000 in the first half of 2025. This growth is attributed to the commercialization of the WiSE CRT System, which received FDA approval in April 2025, and the completion of 46 commercial implants at 23 hospitals during the quarter.

Despite the increase in revenue, EBR Systems reported a net loss of $17.5 million for the second quarter of 2026, up from a loss of $12.0 million in the same quarter of 2025. The loss for the first half of 2026 was $34.5 million, compared to $22.5 million in the prior year. The increase in losses is primarily due to higher operating expenses, particularly in selling, general, and administrative costs, which rose by 92.2% to $10.1 million in the second quarter, and research and development expenses, which increased by 11.2% to $6.6 million.

Operationally, EBR Systems has made strides in expanding its customer base and product adoption. The company trained an additional 48 physicians to implant the WiSE CRT System and signed 32 purchase agreements with target Limited Market Release sites during the first half of 2026. The company’s cash and cash equivalents, along with marketable securities, totaled $86.9 million as of June 30, 2026, a significant increase from $54.2 million at the end of 2025. This increase was largely driven by a capital raise completed in June 2026, which provided $76.3 million in net cash from financing activities.

Looking ahead, EBR Systems faces challenges related to its ongoing operational losses and the need for additional capital to sustain its business. The company has expressed substantial doubt about its ability to continue as a going concern for at least the next twelve months, given its accumulated deficit of $436.7 million and upcoming debt obligations of $41.8 million. To address these concerns, EBR Systems plans to raise additional capital through the issuance of common stock and refinancing its long-term debt obligations. The company has already secured a commitment to purchase 92.1 million CDIs, subject to shareholder approval, which could further bolster its financial position.

In summary, while EBR Systems has made notable progress in revenue generation and operational expansion, it continues to grapple with significant losses and liquidity concerns. The company's future performance will depend on its ability to effectively commercialize the WiSE CRT System and manage its financial obligations.

About EBR Systems, Inc.

EBR Systems, Inc. develops leadless cardiac pacing technology, including the WiSE CRT System, for heart rhythm correction. Its innovative implantable devices deliver ultrasound-based left-ventricle pacing without leads, targeting patients with heart failure unresponsive to conventional therapies. The company focuses on regulatory approval, clinical trials, and commercialization in the U.S. and international markets, emphasizing safety, efficacy, and intellectual property protection in the medical device sector.

This description was generated via AI from an annual report. Updated about 1 year ago.

About 10-Q Filings

A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.

Key points about the 10-Q:

  • Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
  • Content: It includes:
    • Financial statements showing the company's current financial position
    • Updates from management on the performance and projections of the business
    • Information about potential risks the company faces
    • Details on how the company is run internally
  • Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.

Our Methodology

AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.

Our method:

  1. Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
  2. AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
  3. Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
  4. Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
  5. Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Read more about AssetRoom

Feedback & Corrections

Spot an error or have a suggestion? Contact us.

View the complete official filing on the SEC website.

Read on SEC.gov